Cures for Hemophilia A and B? See Also: Why EXEL Was a Loser Yesterday
This content is for members
Pfizer (PFE)
Real Breakthroughs
This content is for members
Yes, the Biotech Evolution Is Speeding. See Also: Allogene Therapeutics, Pfizer and Cellectis
This content is for members
Why Investors Caused a Selloff of Alnylam’s Stock
This content is for members
More Exciting News for Sangamo
Sangamo’s (SGMO) has abundant positive news since it offered proof of concept and feasibility of its zinc finger protein transcription factor …
Cellectis: Offering Proof of Concept is what Led to the Stock Rally
UCART19 UCART19 is one of the Cellectis’ (CLLS) lead allogeneic anti-CD19 CAR T-cell products. The word allogeneic is important as it makes the difference …
Last Week’s Promising News
This content is for members
The Week in Review
This content is for members
Prohost Letter #413
This content is for members
Prohost Letter #412 Part 3
This content is for members
GlycoMimetics: A Lot to Tell at the ASCO Meeting
GlycoMimetics (GLYN) is a development-stage biotechnology company focused on cancer and sickle cell disease. The firm’s most advanced drug, rivipansel, a …
Calming Down PTC Therapeutics Investors’ Concerns. More Good News from Sangamo. AERIE’s Glaucoma Drug NDA
This content is for members
The Value of Sangamo, Merck and AstraZeneca News
This content is for members
Prohost Letter #407
This content is for members
CytomX Therapeutics: A Noteworthy Expansion of Collaborative Agreement with BMY
This content is for members
Prohost Letter #401
This content is for members